Cullinan Associates Inc Arvinas, Inc. Transaction History

Cullinan Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$36.38 - $52.31 $218,280 - $313,860	6,000 New	6,000 $247,000
Q2 2022 Jul 08, 2022	SELL	$36.01 - $74.24 $165,646 - $341,504	-4,600 Reduced 25.14%	13,700 $577,000
Q3 2021 Oct 08, 2021	SELL	$73.2 - $107.87 $1.26 Million - $1.86 Million	-17,200 Reduced 48.45%	18,300 $1.5 Million
Q4 2020 Jan 14, 2021	BUY	$20.19 - $84.93 $716,745 - $3.02 Million	35,500 New	35,500 $3.02 Million

222

68.8M

166K

31.3K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.44B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Cullinan Associates Inc with notifications on news.